search

Active clinical trials for "Neuralgia, Postherpetic"

Results 41-50 of 156

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic...

NeuralgiaPostherpetic

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.

Completed7 enrollment criteria

NGX-4010 for the Treatment of Postherpetic Neuralgia

Herpes ZosterNeuralgia3 more

The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).

Completed11 enrollment criteria

A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)...

Post Herpetic Neuralgia

This study investigated the efficacy of the Lido-Patch (lidocaine 5% medicated plaster) in treatment of pain caused by PHN which is a neuropathic pain syndrome (nerve-related pain conditions) following an acute attack of herpes zoster (shingles).

Completed22 enrollment criteria

Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable...

NeuralgiaNeuralgia; Postherpetic3 more

The investigators will evaluate the effectiveness and safety of acupuncture treatment in refractory neuropathic pain patients.

Completed11 enrollment criteria

Titration Study of ABX-1431

Post Herpetic NeuralgiaDiabetic Peripheral Neuropathy2 more

This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.

Completed18 enrollment criteria

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

This is a Phase II, international multicenter, double-blind, placebo-controlled, crossover study to assess the efficacy of SR419 in PHN subjects.

Completed10 enrollment criteria

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain

PolyneuropathyPeripheral Nerve Injury1 more

The purpose of this trial is to determine if the effect of oxcarbazepine on chronic peripheral nerve pain depends on the supposed mechanism of the pain, ie. if oxcarbazepine mainly relieve pain in patients with irritable nerves.

Completed16 enrollment criteria

Crossover Post-herpetic Neuralgia (PHN)

Post-Herpetic Neuralgia (PHN)

The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with post-herpetic neuralgia (PHN).

Completed13 enrollment criteria

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia...

Postherpetic Neuralgia

This is a Phase 2 randomized, double-blind, placebo-controlled, multiple-dose, multicenter, parallel-group study to evaluate the analgesic activity of ATx08-001, a novel selective peroxisome proliferator-activated receptor modulator (SPPARM), in subjects with moderate-to-severe postherpetic neuralgia pain. Eligible subjects will be randomized to receive either placebo or Atx08-001. Study drug will be administered orally twice a day for 7 days. Subjects will be evaluated for neuropathic pain intensity at regular intervals over a 6 hour period on Day 1 following the first dose of study drug. They will then be discharged from the clinic and will complete diary assessments of pain severity twice a day at home. Subjects will be asked to return to the clinic on Day 8 to complete their last set of pain evaluations.

Completed41 enrollment criteria

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)...

Postherpetic Neuralgia

This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia. The primary hypothesis is that when compared to placebo, treatment with MK-8291 reduces the change from Baseline in participant-reported pain intensity by 1 on an 11-point numeric rating scale.

Completed21 enrollment criteria
1...456...16

Need Help? Contact our team!


We'll reach out to this number within 24 hrs